Brainsway Ltd. (TASE:BRIN) today reported positive interim results from the analysis of its deep TMS (transcranial magnetic stimulation) therapy for Parkinson's disease. The trial led by Dr. Oren Cohen at Sheba Medical Center Tel Hashomer, outside Tel Aviv, found that deep TMS on the prefrontal and motor cortex was safe and effective, and resulted in significant improvement in motor function of patients suffering from Parkinson's disease.
The trial's objective is to test the best parameters for using deep TMS to treat Parkinson's disease. For this purpose, the trial subjects were divided into subgroups. The test group received a combination of frequent treatments of prefrontal cortex and infrequent treatments of the motor cortex. This group showed significant improvement compared with the patients' previous condition as well as compared with the other groups tested along other parameters during the trial.
Brainsway has already recruited 47 patients with Parkinson's disease for the trial. They received 12 treatments over a 30-day period. The researchers said that they intend to conduct a larger clinical trial using the parameters found to be effective compared with the control group, which received a placebo. The trial was double blind.
Brainsway's share price rose 4.8% in morning trading to NIS 8.23, giving a market cap of NIS 332 million.
Published by Globes [online], Israel business news - www.globes-online.com - on October 19, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010